Diabetic Retinopathy - Pipeline Review, H2 2016

Date: November 16, 2016
Pages: 237
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: DEF78385DBEEN
Leaflet:

Download PDF Leaflet

Diabetic Retinopathy - Pipeline Review, H2 2016
Diabetic Retinopathy - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Retinopathy – Pipeline Review, H2 2016, provides an overview of the Diabetic Retinopathy (Metabolic Disorders) pipeline landscape.

Diabetic retinopathy is a complication of diabetes that affects the eyes. Diabetic retinopathy symptoms may include spots or dark strings floating in your vision (floaters), blurred vision, fluctuating vision, vision loss and difficulty with color perception. The predisposing factors include diabetes, high blood pressure, high cholesterol, pregnancy and tobacco use.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diabetic Retinopathy – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Diabetic Retinopathy (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Retinopathy (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Retinopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 9, 5, 1, 33, 12 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 7 molecules, respectively.Diabetic Retinopathy.

Diabetic Retinopathy (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Retinopathy (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Diabetic Retinopathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Diabetic Retinopathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Diabetic Retinopathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Retinopathy (Metabolic Disorders)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Diabetic Retinopathy (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Diabetic Retinopathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Diabetic Retinopathy Overview
Therapeutics Development
Pipeline Products for Diabetic Retinopathy - Overview
Pipeline Products for Diabetic Retinopathy - Comparative Analysis
Diabetic Retinopathy - Therapeutics under Development by Companies
Diabetic Retinopathy - Therapeutics under Investigation by Universities/Institutes
Diabetic Retinopathy - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Diabetic Retinopathy - Products under Development by Companies
Diabetic Retinopathy - Products under Investigation by Universities/Institutes
Diabetic Retinopathy - Companies Involved in Therapeutics Development
Acucela Inc.
Aerie Pharmaceuticals, Inc.
Aerpio Therapeutics, Inc.
Amakem NV
Antisense Therapeutics Limited
Araim Pharmaceuticals, Inc.
BCN Peptides, S.A.
Biomar Microbial Technologies
Charlesson LLC.
Coherus BioSciences, Inc.
Crinetics Pharmaceuticals, Inc.
Diffusion Pharmaceuticals Inc
Dimerix Bioscience Pty Ltd
Dynamis Therapeutics, Inc.
EyeGene Inc
Foresee Pharmaceuticals, LLC
Formycon AG
Icon Bioscience, Inc.
Islet Sciences, Inc.
Kodiak Sciences Inc.
Kowa Company, Ltd.
LegoChem Biosciences, Inc
Lpath, Inc.
M's Science Corporation
Mabion SA
MingSight Pharmaceuticals
OcuCure Therapeutics, Inc.
Oculis ehf
Ohr Pharmaceutical Inc.
PanOptica, Inc.
Profarma
Promedior, Inc.
Regeneron Pharmaceuticals Inc
Retrotope, Inc
Ribomic Inc.
Stelic Institute & Co., Inc.
Stemedica Cell Technologies, Inc.
Strongbridge Biopharma plc
Sucampo Pharmaceuticals, Inc.
Targazyme, Inc.
ThromboGenics NV
TWi Pharmaceuticals, Inc.
VESSL Therapeutics Ltd
Diabetic Retinopathy - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(irbesartan + propagermanium) - Drug Profile
A-717 - Drug Profile
AC-301 - Drug Profile
aflibercept - Drug Profile
AKB-9778 - Drug Profile
ALG-1001 - Drug Profile
AMA-0428 - Drug Profile
APTA-1004 - Drug Profile
Aptamers for Diabetic Retinopathy - Drug Profile
AR-13154 - Drug Profile
atesidorsen sodium - Drug Profile
Biologics to Inhibit Semaphorin 3A and VEGF for Diabetic Complications - Drug Profile
BNN-27 - Drug Profile
cibinetide - Drug Profile
CLT-005 - Drug Profile
CLT-020 - Drug Profile
COR-005 - Drug Profile
cyclosporine - Drug Profile
Cyndacel-M - Drug Profile
DMX-400 - Drug Profile
Drug to Activate EGF-Like-Domain Multiple 7 for Oncology and Diabetic Retinopathy - Drug Profile
DT-23552 - Drug Profile
DYN-12 - Drug Profile
E-1086 - Drug Profile
EG-Mirotin - Drug Profile
emixustat hydrochloride - Drug Profile
FP-008 - Drug Profile
GLY-230 - Drug Profile
IB-09A0133 - Drug Profile
IVMED-60 - Drug Profile
JP-153 - Drug Profile
KSI-301 - Drug Profile
L-779976 - Drug Profile
LCB-030110 - Drug Profile
Monoclonal Antibody to Inhibit IAP for Diabetic Retinopathy - Drug Profile
Monoclonal Antibody to Inhibit LRG1 for AMD, Diabetic Retinopathy, Oncology and Scar - Drug Profile
MS-553 - Drug Profile
MultiGeneEye - Drug Profile
Nextomabs - Drug Profile
NM-108 - Drug Profile
OC-10X - Drug Profile
OC-410 - Drug Profile
ocriplasmin - Drug Profile
OCU-200 - Drug Profile
OCX-063 - Drug Profile
OLX-302 - Drug Profile
PAN-90806 - Drug Profile
PF-07 - Drug Profile
PRM-167 - Drug Profile
Protein for Oncology, Ophthalmology and Metabolic Disorders - Drug Profile
ranibizumab biosimilar - Drug Profile
ranibizumab biosimilar - Drug Profile
ranibizumab biosimilar - Drug Profile
RBM-008 - Drug Profile
Recombinant Protein for Oncology and Diabetic Retinopathy - Drug Profile
Recombinant Protein To Target Caspases for Diabetic Retinopathy, Macular Degeneration and Solid Tumor - Drug Profile
RES-529 - Drug Profile
ripasudil - Drug Profile
RT-001 - Drug Profile
RT-002 - Drug Profile
RTU-1096 - Drug Profile
somatostatin - Drug Profile
squalamine lactate - Drug Profile
Stem Cell Therapy for Bacterial Sepsis, Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease and Toxicology - Drug Profile
Stem Cell Therapy for Diabetic Retinopathy - Drug Profile
STNM-1510 - Drug Profile
Synthetic Peptide to Agonize PEDF-R for Diabetic Retinopathy - Drug Profile
THR-687 - Drug Profile
TZ-101 - Drug Profile
V-1932 - Drug Profile
Wnt-001 - Drug Profile
Diabetic Retinopathy - Dormant Projects
Diabetic Retinopathy - Discontinued Products
Diabetic Retinopathy - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 232

LIST OF TABLES

Number of Products under Development for Diabetic Retinopathy, H2 2016
Number of Products under Development for Diabetic Retinopathy - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Development by Companies, H2 2016 (Contd..2)
Number of Products under Development by Companies, H2 2016 (Contd..3)
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Products under Development by Companies, H2 2016 (Contd..3)
Products under Investigation by Universities/Institutes, H2 2016
Diabetic Retinopathy - Pipeline by Acucela Inc., H2 2016
Diabetic Retinopathy - Pipeline by Aerie Pharmaceuticals, Inc., H2 2016
Diabetic Retinopathy - Pipeline by Aerpio Therapeutics, Inc., H2 2016
Diabetic Retinopathy - Pipeline by Amakem NV, H2 2016
Diabetic Retinopathy - Pipeline by Antisense Therapeutics Limited, H2 2016
Diabetic Retinopathy - Pipeline by Araim Pharmaceuticals, Inc., H2 2016
Diabetic Retinopathy - Pipeline by BCN Peptides, S.A., H2 2016
Diabetic Retinopathy - Pipeline by Biomar Microbial Technologies, H2 2016
Diabetic Retinopathy - Pipeline by Charlesson LLC., H2 2016
Diabetic Retinopathy - Pipeline by Coherus BioSciences, Inc., H2 2016
Diabetic Retinopathy - Pipeline by Crinetics Pharmaceuticals, Inc., H2 2016
Diabetic Retinopathy - Pipeline by Diffusion Pharmaceuticals Inc, H2 2016
Diabetic Retinopathy - Pipeline by Dimerix Bioscience Pty Ltd, H2 2016
Diabetic Retinopathy - Pipeline by Dynamis Therapeutics, Inc., H2 2016
Diabetic Retinopathy - Pipeline by EyeGene Inc, H2 2016
Diabetic Retinopathy - Pipeline by Foresee Pharmaceuticals, LLC, H2 2016
Diabetic Retinopathy - Pipeline by Formycon AG, H2 2016
Diabetic Retinopathy - Pipeline by Icon Bioscience, Inc., H2 2016
Diabetic Retinopathy - Pipeline by Islet Sciences, Inc., H2 2016
Diabetic Retinopathy - Pipeline by Kodiak Sciences Inc., H2 2016
Diabetic Retinopathy - Pipeline by Kowa Company, Ltd., H2 2016
Diabetic Retinopathy - Pipeline by LegoChem Biosciences, Inc, H2 2016
Diabetic Retinopathy - Pipeline by Lpath, Inc., H2 2016
Diabetic Retinopathy - Pipeline by M's Science Corporation, H2 2016
Diabetic Retinopathy - Pipeline by Mabion SA, H2 2016
Diabetic Retinopathy - Pipeline by MingSight Pharmaceuticals, H2 2016
Diabetic Retinopathy - Pipeline by OcuCure Therapeutics, Inc., H2 2016
Diabetic Retinopathy - Pipeline by Oculis ehf, H2 2016
Diabetic Retinopathy - Pipeline by Ohr Pharmaceutical Inc., H2 2016
Diabetic Retinopathy - Pipeline by PanOptica, Inc., H2 2016
Diabetic Retinopathy - Pipeline by Profarma, H2 2016
Diabetic Retinopathy - Pipeline by Promedior, Inc., H2 2016
Diabetic Retinopathy - Pipeline by Regeneron Pharmaceuticals Inc, H2 2016
Diabetic Retinopathy - Pipeline by Retrotope, Inc, H2 2016
Diabetic Retinopathy - Pipeline by Ribomic Inc., H2 2016
Diabetic Retinopathy - Pipeline by Stelic Institute & Co., Inc., H2 2016
Diabetic Retinopathy - Pipeline by Stemedica Cell Technologies, Inc., H2 2016
Diabetic Retinopathy - Pipeline by Strongbridge Biopharma plc , H2 2016
Diabetic Retinopathy - Pipeline by Sucampo Pharmaceuticals, Inc., H2 2016
Diabetic Retinopathy - Pipeline by Targazyme, Inc., H2 2016
Diabetic Retinopathy - Pipeline by ThromboGenics NV, H2 2016
Diabetic Retinopathy - Pipeline by TWi Pharmaceuticals, Inc., H2 2016
Diabetic Retinopathy - Pipeline by VESSL Therapeutics Ltd, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Diabetic Retinopathy - Dormant Projects, H2 2016
Diabetic Retinopathy - Dormant Projects (Contd..1), H2 2016
Diabetic Retinopathy - Dormant Projects (Contd..2), H2 2016
Diabetic Retinopathy - Dormant Projects (Contd..3), H2 2016
Diabetic Retinopathy - Dormant Projects (Contd..4), H2 2016
Diabetic Retinopathy - Dormant Projects (Contd..5), H2 2016
Diabetic Retinopathy - Discontinued Products, H2 2016 223

LIST OF FIGURES

Number of Products under Development for Diabetic Retinopathy, H2 2016
Number of Products under Development for Diabetic Retinopathy - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Top 10 Routes of Administration, H2 2016
Number of Products by Stage and Top 10 Routes of Administration, H2 2016
Number of Products by Top 10 Molecule Types, H2 2016
Number of Products by Stage and Top 10 Molecule Types, H2 2016
Skip to top


Ask Your Question

Diabetic Retinopathy - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: